• Abbott Laboratories recently announced a multi-year partnership with Google Health to integrate glucose insights from its Lingo biowearable into the Google Health app, using artificial intelligence to deliver personalized metabolic health coaching and unify glucose, activity, sleep, and wellness data.
• A particularly important aspect of this collaboration is the planned large-scale metabolic health study, which could deepen scientific understanding of how everyday behaviors affect long-term health and inform future digital health tools.
• We’ll now examine how this AI-powered integration of Lingo glucose data into Google Health could reshape Abbott’s existing investment narrative.

Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

Abbott Laboratories Investment Narrative Recap

To own Abbott, you need to believe in its ability to compound value through diversified medical devices, diagnostics, and consistent dividends, while managing margin pressure and regulatory risk. The Google Health partnership reinforces Abbott’s diabetes and digital health positioning but does not materially change the near term focus on defending pricing power in continuous glucose monitoring or the broader risk from tariffs, FX, and litigation.

Among recent announcements, Abbott’s Q2 2026 results are most relevant here, as they highlighted solid device and diagnostics demand alongside lower profit margins and elevated valuation concerns. The Lingo and Google Health integration slots into that context as a potential long term support for the diabetes franchise at a time when investors are watching earnings quality, pricing pressure, and competitive bidding in CGM particularly closely.

Yet investors should be aware that while digital partnerships may support demand, competitive bidding and pricing pressure in CGM could still...

Abbott Laboratories' narrative projects $60.4 billion revenue and $9.5 billion earnings by 2029. This requires 9.0% yearly revenue growth and about a $4.1 billion earnings increase from $5.4 billion today.

Uncover how Abbott Laboratories' forecasts yield a $119.12 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community cluster between US$118.42 and US$149.90, reminding you that individual assessments can vary widely. Set against this, the key dependency on Abbott defending CGM pricing and margins gives important context for how such valuations might hold up over time.

Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth just $118.42!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 57 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.